Stock TLPH TALPHERA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Talphera, Inc.

Equities

TLPH

US00444T2096

Delayed Nasdaq
Other stock markets
 15:54:10 2024-04-29 EDT 		5-day change 1st Jan Change
0.9952 USD -5.22% Intraday chart for Talphera, Inc. +5.39% +33.35%
03-06 Talphera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-06 Transcript : Talphera, Inc., Q4 2023 Earnings Call, Mar 06, 2024

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alliance Global Initiates AcelRx Pharmaceuticals at Buy With $4.25 Price Target
MT
HC Wainwright Adjusts AcelRx Pharmaceuticals Price Target to $5 From $8, Maintains Buy Rating
MT
HC Wainwright Upgrades AcelRx Pharmaceuticals to Buy From Neutral, Price Target is $8
MT
HC Wainwright Downgrades AcelRx Pharmaceuticals to Neutral from Buy
MT
Cantor Fitzgerald Lowers Price Target for AcelRx Pharmaceuticals to $4 From $9, Maintains Overweight Rating
MT
ACELRX PHARMACEUTICALS : HC Wainwright Adjusts Price Target on AcelRx Pharmaceuticals to $5 From $7, Maintains Buy Rating
MT
AcelRx Pharmaceuticals, Inc. Announces Clinical Data Reporting High Ratings for Healthcare Professional and Patient Satisfaction Following Use of Dsuvia for Acute Pain in Hospital Settings
CI
ACELRX PHARMACEUTICALS : Credit Suisse Adjusts AcelRx Pharmaceuticals' Price Target to $0.83 From $0.84, Reiterates Underperform Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TLPH Stock
  4. News Talphera, Inc.
  5. Analyst Reco.